#ASH24: Treatment for relapsed/refractory ALL

Stay up to date with the latest developments in treatment for relapsed/refractory acute lymphoblastic leukemia from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition with our live social media coverage.  

CONGRESS #ASH24 | PRESENTATION
Erica Brivio, Princess Máxima Center for Pediatric Oncology discussed the ITCC-059 trial, on Inotuzumab Ozogamicin treatment in Children with CD22+ BCP-ALL. The only significant risk factor for sinusoidal obstruction syndrome was the time from last… pic.twitter.com/BnBCMDcirp

— ALL Hub (@ALL_Hub_) December 8, 2024

CONGRESS #ASH24 | PRESENTATION
Ibrahim Muhsen, @bcmhouston discussed efficacy and safety of brexucabtagene autoleucel in older pts with R/R B-ALL. There was no difference in PFS or OS across age groups. Older patients did not require higher rates of prophylaxis. Using bruxu-cel… pic.twitter.com/upouwVyY7h

— ALL Hub (@ALL_Hub_) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Hua Zhang presents results from a study assessing the safety and efficacy of bicistronic CD19/CD22-targeted CAR-T cell therapy in pediatric patients with R/R B-ALL.
Treatment was well tolerated, and the 1-year EFS and OS rates were 75.5% and… pic.twitter.com/mPuPapGLxa

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS | #ASH24 | POSTER
Jaromir Tomasik from Medical University of Warsaw shares finding from a meta-analysis of response rates to 1L salvage treatment after anti-CD19 CAR T-cell therapy failure in adult patients with B-ALL. The most common salvage treatments identified were… pic.twitter.com/Psmsdfy0HT

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS | #ASH24 | POSTER
Erlie Jiang from the Chinese Academy of Medical Sciences shares real-world data for dose-adjusted InO in adult patients with newly diagnosed (n=12), MRD-positive (n=19) or R/R (n=13) B-ALL. Dose-adjusted InO was a well-tolerated and effective treatment… pic.twitter.com/ubPaF1WfKR

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION
Andrew Hughes @ChildrensPhila highlights results from an analysis of the phase III AALL1331 trial.
The protein TCL1A was more abundant in pediatric patients with B-ALL who responded to blinatumomab vs non-responders.
Follow our live feed for more… pic.twitter.com/3uKbICdalC

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Ibrahim Aldoss @cityofhope spoke about relapse risk in pts with B-ALL with TP53 mutation treated with blinatumomab. Allo HSCT reduces relapse post-blina. TP53 mutation predicts inferior outcomes. Follow our live feed for more updates:… pic.twitter.com/RhYZU9YNut

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION@NicBoissel, @HopSaintLouis discussed CNS relapse in Ph- ALL. Male pts, and high WBC count increased risk of CNS relapse. EOI-MRD was associated with decreased risk on CNS relapse. CNS irradiation and TBI-based HSCT also decreased risk of CNS… pic.twitter.com/km18EiOivV

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Daniel J. DeAngelo, @DanaFarber spoke about how to optimize dosing of Inotuzumab Ozogamicin in R/R ALL. Results from the phase IV study B1931030 showed similar efficacy across all doses. Higher InO exposure led to higher CR rates. Follow our live… pic.twitter.com/kAnVJ2NV2o

— ALL Hub (@ALL_Hub_) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION
Elias Jabbour @MDAndersonNews, shared an analysis from the FELIX study examining the correlation between MRD-negative remission and outcomes in adult patients with B-ALL treated with the CAR T-cell therapy obe-cel. The majority of patients treated… pic.twitter.com/9N6sppEQvj

— ALL Hub (@ALL_Hub_) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Susana Rives @SJDbarcelona_es shared results from a retrospective study investigating outcomes associated with second infusion of CAR T-cells in patients with R/R B-ALL. Second infusion was associated with low toxicity and a transient MRD negative… pic.twitter.com/Lowa5eObDa

— ALL Hub (@ALL_Hub_) December 10, 2024